Skip to main content
Erschienen in: International Journal of Hematology 3/2019

03.01.2019 | Original Article

Clinical features of dyskeratosis congenita in mainland China: case reports and literature review

verfasst von: Fuxing Li, Wei Li, Xiaohong Qiao, Xiaotian Xie

Erschienen in: International Journal of Hematology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Dyskeratosis congenita (DC) is a rare-inherited bone marrow failure syndrome associated with multi-system disorder. To summarize the clinical features, epidemiology, and treatment of DC in mainland China, we retrospectively reviewed the medical records of two patients diagnosed with DC at our hospital and published reports on other DC patients in mainland China. The clinical features of 82 DC patients were summarized. The median age of onset was 5 years, but the median age at diagnosis was 16 years. Bone marrow failure occurred at a high rate of 44% and early, with a median onset age of 6 years (range 1–40 years). Only DKC1, TINF2, and TERT mutations were reported, which is a relatively simple signature. Aplastic anemia was treated mainly with low-dose androgens, glucocorticoids, or allogeneic hematopoietic stem cell transplantation, with an efficacy of 39% (14/36). In China, DC is relatively common in infants, with early age of onset but delayed diagnosis. Bone marrow failure occurred at a high rate and early. Improvement in the knowledge and awareness of DC combined with gene mutation tests will facilitate diagnosis and therapy in its early stages.
Literatur
1.
Zurück zum Zitat Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. J Hematop. 2011;4:53–60.CrossRef Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. J Hematop. 2011;4:53–60.CrossRef
2.
Zurück zum Zitat Fuente JDL, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant. 2007;11:584–94.CrossRefPubMed Fuente JDL, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant. 2007;11:584–94.CrossRefPubMed
3.
Zurück zum Zitat De BK, Degreef H, Verwilghen R, Corbeel L, Casteels Van DM. Thrombocytopenia: first symptom in a patient with dyskeratosis congenita. Pediatrics. 1981;7:898–903. De BK, Degreef H, Verwilghen R, Corbeel L, Casteels Van DM. Thrombocytopenia: first symptom in a patient with dyskeratosis congenita. Pediatrics. 1981;7:898–903.
4.
Zurück zum Zitat Dokal I, Vulliamy T, Mason P, Bessler M. Clinical utility gene card for: dyskeratosis congenita. Eur J Hum Genet. 2011;19:1–11.CrossRef Dokal I, Vulliamy T, Mason P, Bessler M. Clinical utility gene card for: dyskeratosis congenita. Eur J Hum Genet. 2011;19:1–11.CrossRef
7.
Zurück zum Zitat Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol. 2010;92:419–24.CrossRefPubMed Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol. 2010;92:419–24.CrossRefPubMed
8.
Zurück zum Zitat Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.CrossRefPubMed Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.CrossRefPubMed
10.
Zurück zum Zitat Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol. 2015;103:990–6.CrossRef Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol. 2015;103:990–6.CrossRef
11.
Zurück zum Zitat Doka I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011; 2011:480–6.CrossRef Doka I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011; 2011:480–6.CrossRef
12.
Zurück zum Zitat Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013;6(3):327–37.CrossRefPubMed Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013;6(3):327–37.CrossRefPubMed
13.
Zurück zum Zitat Zhang JY, An WB, Zhang L, Chang LX, Qi BQ, Liu TF, et al. Genotype analysis and telomere length measure in patients with dyskeratosis congenita. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:212–6.PubMed Zhang JY, An WB, Zhang L, Chang LX, Qi BQ, Liu TF, et al. Genotype analysis and telomere length measure in patients with dyskeratosis congenita. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:212–6.PubMed
14.
Zurück zum Zitat Liu X, Li XY, Deng WP, Dong X, Zhang QLX, Hu ZZ. Telomere length in patients with dyskeratosis congenita in a Chinese Family. Int J Genet. 2012;35:157–60. Liu X, Li XY, Deng WP, Dong X, Zhang QLX, Hu ZZ. Telomere length in patients with dyskeratosis congenita in a Chinese Family. Int J Genet. 2012;35:157–60.
15.
Zurück zum Zitat Zhou A, Xia XX, Chen Z, Li FZL, Liang XS. Bone marrow transplantation in the treatment of two cases of dyskeratosis congenita. Zhonghua Xue Ye Xue Za Zhi. 2001;22:407. Zhou A, Xia XX, Chen Z, Li FZL, Liang XS. Bone marrow transplantation in the treatment of two cases of dyskeratosis congenita. Zhonghua Xue Ye Xue Za Zhi. 2001;22:407.
17.
Zurück zum Zitat Savage SA, Dokal I, Armanios M, Aubert G, Cowen EW, Domingo DL, et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer. 2009;53:520–3.CrossRefPubMedPubMedCentral Savage SA, Dokal I, Armanios M, Aubert G, Cowen EW, Domingo DL, et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer. 2009;53:520–3.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin N Am. 2009;23:215–31.CrossRef Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin N Am. 2009;23:215–31.CrossRef
19.
20.
Zurück zum Zitat Kumar S, Suthar R. Dyskeratosis Congenita. Br J Oral Surg. 2013;15:56–8. Kumar S, Suthar R. Dyskeratosis Congenita. Br J Oral Surg. 2013;15:56–8.
21.
Zurück zum Zitat Dean A, Alamillos FJ, Velez A, Velasco F, Rodas J, Garcia A. Squamous cell carcinoma of the oral cavity and Fanconi’s anemia. An association to bear in mind. Med Oral. 1999;4:410–5.PubMed Dean A, Alamillos FJ, Velez A, Velasco F, Rodas J, Garcia A. Squamous cell carcinoma of the oral cavity and Fanconi’s anemia. An association to bear in mind. Med Oral. 1999;4:410–5.PubMed
23.
Zurück zum Zitat Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott–Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66.CrossRefPubMedPubMedCentral Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott–Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med. 2014; 2014(default):157–67. Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med. 2014; 2014(default):157–67.
25.
Zurück zum Zitat Elmahadi S, Muramatsu H, Kojima S. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita. Curr Opin Hematol. 2016;23:501–7.CrossRefPubMed Elmahadi S, Muramatsu H, Kojima S. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita. Curr Opin Hematol. 2016;23:501–7.CrossRefPubMed
26.
Zurück zum Zitat Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165:349–57.CrossRefPubMedPubMedCentral Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165:349–57.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Agarwal S. Evaluation and management of hematopoietic failure in dyskeratosis congenita. Hematol Oncol Clin N Am. 2018;32:669–85.CrossRef Agarwal S. Evaluation and management of hematopoietic failure in dyskeratosis congenita. Hematol Oncol Clin N Am. 2018;32:669–85.CrossRef
28.
Zurück zum Zitat Kirwan M, Beswick R, Yulliamy T, Nathwani AC, Walne AJ, Casimir C. Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients. Br J Haematol. 2009;144:771–81.CrossRefPubMed Kirwan M, Beswick R, Yulliamy T, Nathwani AC, Walne AJ, Casimir C. Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients. Br J Haematol. 2009;144:771–81.CrossRefPubMed
30.
Zurück zum Zitat Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere, biology disorders. Genet Med. 2010;12:753–64.CrossRefPubMed Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere, biology disorders. Genet Med. 2010;12:753–64.CrossRefPubMed
32.
Zurück zum Zitat Yamaguchi H, Sakaguchi H, Yoshida K, Yabe M, Yabe H, Okuno Y, et al. Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. Int J Hematol. 2015;102:544–52.CrossRefPubMed Yamaguchi H, Sakaguchi H, Yoshida K, Yabe M, Yabe H, Okuno Y, et al. Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. Int J Hematol. 2015;102:544–52.CrossRefPubMed
33.
Zurück zum Zitat Xu J, Khincha PP, Giri N, Alter BP, Savage SA, Wong JM. Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations. Am J Hematol. 2016;91:1215–20.CrossRefPubMed Xu J, Khincha PP, Giri N, Alter BP, Savage SA, Wong JM. Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations. Am J Hematol. 2016;91:1215–20.CrossRefPubMed
Metadaten
Titel
Clinical features of dyskeratosis congenita in mainland China: case reports and literature review
verfasst von
Fuxing Li
Wei Li
Xiaohong Qiao
Xiaotian Xie
Publikationsdatum
03.01.2019
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-02582-x

Weitere Artikel der Ausgabe 3/2019

International Journal of Hematology 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.